ERBB2 and breast carcinoma: According to the 2020 NCCN guideline, the preferred neoadjuvant therapy for HER2‐positive breast cancer were four cycles of doxorubicin and cyclophosphamide followed by four cycles of paclitaxel plus trastuzumab (AC‐TH) with or without pertuzumab.14